Elahere was found to improve survival in patients with FR-alpha–positive, platinum-resistant, high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/ema-backs-approval-elahere-ovarian-cancer-2024a1000h5l?src=rss
Author :
Publish date : 2024-09-20 14:43:51
Copyright for syndicated content belongs to the linked Source.
